← Human Trials & Peer-Reviewed Studies

Long-Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial.

Plain-language guide to PMID 36661855 (2023): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 303 women.

Key Facts

PMID
36661855
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Year
2023
Study type
Randomized Controlled Trial
Authors
Pérez-Castrillón JL et al. (18 authors)
DOI
10.1002/jbmr.4776

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Vitamin D plays a major role in bone health and probably also in multiple extraskeletal acute and chronic diseases.

By month 4, stable 25(OH)D levels were documented with both calcifediol and cholecalciferol (intention-to-treat population): 26.8 ± 8.5 ng/mL (Group A1) and 23.1 ± 5.4 ng/mL (Group B).

Who Took Part

The abstract describes 303 women taking part.

PubMed tags the participants as women only.

A total of 303 women were randomized and 298 evaluated.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled, multicenter and parallel-group study.

The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some women received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

More than one site took part, so the women came from several places.

What Was Measured

By month 4, stable 25(OH)D levels were documented with both calcifediol and cholecalciferol (intention-to-treat population): 26.8 ± 8.5 ng/mL (Group A1) and 23.1 ± 5.4 ng/mL (Group B).

By month 12, 25(OH)D levels were 23.9 ± 8.0 ng/mL (Group A1) and 22.4 ± 5.5 ng/mL (Group B).

PubMed files the paper under topics including Calcifediol, Postmenopause, Vitamin D, Cholecalciferol, Vitamin D Deficiency and Dietary Supplements.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 303 women.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2023 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.